Home | Welcome to Contract Pharma   
Last Updated Friday, April 18 2014
Print

Pfizer Acquires NextWave



Published November 28, 2012
Related Searches: Development
Pfizer has acquired NextWave Pharmaceuticals, a privately held specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).
 
Pfizer now has exclusive North American commercialization rights to Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, the first once-daily liquid medication approved in the U.S. to treat ADHD. Quillivant XR was approved by the FDA in September and is expected to be available in January 2013. Financial terms of the acquisitions were not disclosed


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On